All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis?
Video series
ASH 2020 highlights for myelofibrosis
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Srdan Verstovsek, MD Anderson Cancer Center, Houston, US. We asked, Does the bromodomain and extraterminal domain (BET) inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis (MF)?
The use of the JAK inhibitor ruxolitinib is standard practice for most patients with MF. However, it does not control all the systemic symptoms in all patients. In this video, Verstovsek discusses the results of the phase II MANIFEST study investigating the BET inhibitor CPI-0610 in combination with ruxolitinib in patients with MF.
Video series
ASH 2020 highlights for myelofibrosis
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox